+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Schizophrenia Market Report and Forecast 2024-2032

  • PDF Icon

    Report

  • 160 Pages
  • April 2024
  • Region: Global
  • Expert Market Research
  • ID: 5960393

Schizophrenia Market Overview

The schizophrenia market size was valued at USD 7.78 billion in 2023, driven by the rising incidence of the disease along with heightened awareness surrounding mental health disorders across the 8 major markets. The market is expected to grow at a CAGR of 5.80% during the forecast period of 2024-2032, with the values likely to rise from USD 8.23 billion in 2024 to USD 12.92 billion by 2032.

The schizophrenia market is a segment of the central nervous system (CNS) therapeutics market that focuses on the treatment of schizophrenia, a chronic and severe mental disorder that affects how a person thinks, feels, and behaves. Schizophrenia is characterized by positive symptoms (such as hallucinations, delusions, and disorganized speech), negative symptoms (such as reduced emotional expression, social withdrawal, and lack of motivation), and cognitive impairments (such as problems with attention, memory, and executive functions).

The growth of the market is driven by several factors, such as the increasing prevalence of schizophrenia, the rising awareness and diagnosis of the disorder, the availability of new and improved therapies, and the unmet medical needs of patients.

Schizophrenia Market Drivers and Constraints

The following are some of the key drivers that influence the schizophrenia market:

  • Increasing prevalence of schizophrenia: Schizophrenia affects about 24 million people, according to the World Health Organization (WHO). The prevalence of schizophrenia varies by region, age, gender, and socioeconomic status, but it is generally higher in low- and middle-income countries, in urban areas, in males, and in young adults. The increasing prevalence of schizophrenia is attributed to various factors, such as genetic susceptibility, environmental stressors, substance abuse, migration, and urbanization.
  • Rising awareness and diagnosis of schizophrenia: Schizophrenia is often underdiagnosed and undertreated, especially in developing countries, due to the lack of mental health resources, trained professionals, and screening tools. However, in recent years, there has been a growing awareness and recognition of schizophrenia as a serious and treatable mental disorder, thanks to the efforts of various organizations, such as the WHO, the National Alliance on Mental Illness (NAMI), and the Schizophrenia and Related Disorders Alliance of America (SARDAA). These organizations provide education, advocacy, and support for patients, families, and caregivers, and promote early detection and intervention of schizophrenia.
  • Availability of new and improved therapies: The current pharmacological treatment of schizophrenia mainly consists of antipsychotic drugs, which can reduce the positive symptoms but have limited effects on the negative and cognitive symptoms. Moreover, antipsychotic drugs often cause serious side effects, such as weight gain, metabolic syndrome, extrapyramidal symptoms, and tardive dyskinesia. Therefore, there is a high demand for new and improved therapies that can address the unmet medical needs of patients with schizophrenia. Several novel agents, such as glutamate modulators, serotonin modulators, dopamine modulators, and cannabinoid receptor agonists, are under development and may offer better efficacy, safety, and tolerability profiles than existing drugs.
  • Unmet medical needs of patients: Despite the availability of various therapies, many patients with schizophrenia remain symptomatic, functionally impaired, and socially isolated. Patients with schizophrenia face various challenges, such as stigma, discrimination, poverty, homelessness, violence, and suicide. Therefore, there is a need for more comprehensive and holistic approaches that can improve the clinical and psychosocial outcomes of patients with schizophrenia.

Constraints:

  • High Cost of Treatment: The high cost of novel antipsychotic medications limits access for patients in lower-income countries.
  • Treatment Adherence Issues: The complexity of schizophrenia management and side effects of medications often lead to poor treatment adherence.
  • Limited Access to Healthcare Services: In many regions, limited access to mental health services and specialists hinders effective treatment of schizophrenia.

Schizophrenia Market Trends and Developments

The following are some of the key trends and developments that shape the schizophrenia market:

  • Advancements in Antipsychotic Medications: There is a continuous effort to develop new antipsychotic drugs with fewer side effects, improved efficacy, and better patient adherence. Long-acting injectable (LAI) antipsychotics are gaining popularity due to their convenience and ability to ensure consistent medication levels.
  • Personalized Medicine: Researchers are exploring the use of genetic testing and biomarkers to tailor treatments to individual patients, enhancing the effectiveness of schizophrenia management and reducing adverse effects.
  • Integration of Digital Health Tools: The use of digital health technologies, such as smartphone apps and wearable devices, is increasing in the management of schizophrenia. These tools can help monitor symptoms, medication adherence, and provide early intervention for relapses.
  • Focus on Cognitive Symptoms: There is a growing emphasis on addressing the cognitive symptoms of schizophrenia, such as memory and attention deficits, which significantly impact daily functioning and quality of life. New treatments targeting these symptoms are being explored.
  • Expansion of Psychosocial Interventions: Alongside pharmacological treatments, there is an increased focus on psychosocial interventions, such as cognitive-behavioral therapy (CBT), social skills training, and supported employment, to provide comprehensive care for individuals with schizophrenia.
  • Early Intervention Programs: Early intervention services for individuals at high risk of developing schizophrenia or in the early stages of the disorder are being expanded, as early treatment is associated with better outcomes.
  • Rising Awareness and Destigmatization: Efforts to raise awareness about schizophrenia and reduce stigma are ongoing, aiming to improve access to care and support for individuals affected by the disorder.
  • Global Health Initiatives: Global initiatives are addressing the need for improved mental health services and access to treatments for schizophrenia in low- and middle-income countries.

Schizophrenia Market Segmentation

The schizophrenia market is segmented by type, treatment, route of administration, end user, distribution channel, and region.

Market Breakup by Type

  • Paranoid Schizophrenia
  • Hebephrenic Schizophrenia
  • Catatonic Schizophrenia
  • Undifferentiated Schizophrenia

Market Breakup by Treatment

  • Second Generation Antipsychotics
  • Invega (Paliperidone)
  • Zyprexa (Olanzapine)
  • Geodon (Ziprasidone)
  • Seoquel(Quetiapine)
  • Latuda (Lurasidone)
  • Saphris (Asenapine)
  • Vraylar (Cariprazine)
  • Risperdal (Risperidone)
  • Third Generation Antipsychotics
  • Abilify (Aripiprazole)

Market Breakup by Route of Administration

  • Oral
  • Injectable
  • Spinal Tap
  • Muscle Biopsy
  • Others

Market Breakup by End User

  • Hospitals & Clinics
  • Cancer Research Centers
  • Others

Market Breakup by Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

Market Breakup by Region

  • United States
  • EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Japan
  • India

Schizophrenia Market: Competitive Landscape

The schizophrenia market is highly competitive and fragmented, with several large and small players operating in the market. The competitive landscape is marked by the presence of major pharmaceutical companies that dominate the market, including Johnson & Johnson, Bristol Myers Squibb, AstraZeneca, Pfizer, Novartis, Eli Lilly & Company, Sumitomo Dainippon Pharma, Vanda Pharmaceuticals, Allergan, H. Lundbeck A/S, Alkermes plc, AbbVie Inc., and Acadia Pharmaceuticals among others. These companies are engaged in extensive R&D activities to develop new and improved treatments.


This product will be delivered within 5-7 business days.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Schizophrenia Market Overview - 8 Major Markets
3.1 Schizophrenia Market Historical Value (2017-2023)
3.2 Schizophrenia Market Forecast Value (2024-2032)
4 Schizophrenia Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Schizophrenia Epidemiology Scenario and Forecast - 8 Major Markets
6.1 8MM Epidemiology Scenario Overview (2017-2032)
6.2 United States Schizophrenia Epidemiology Scenario and Forecast (2017-2032)
6.3 EU-4 and United Kingdom Schizophrenia Epidemiology Scenario and Forecast (2017-2032)
6.3.1 Germany Schizophrenia Epidemiology Scenario and Forecast (2017-2032)
6.3.2 France Schizophrenia Epidemiology Scenario and Forecast (2017-2032)
6.3.3 Italy Schizophrenia Epidemiology Scenario and Forecast (2017-2032)
6.3.4 Spain Schizophrenia Epidemiology Scenario and Forecast (2017-2032)
6.3.5 United Kingdom Schizophrenia Epidemiology Scenario and Forecast (2017-2032)
6.4 Japan Schizophrenia Epidemiology Scenario and Forecast (2017-2032)
6.5 India Schizophrenia Epidemiology Scenario and Forecast (2017-2032)
7 Schizophrenia Market Landscape - 8 Major Markets
7.1 Schizophrenia: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Schizophrenia: Product Landscape
7.2.1 Analysis by Type
7.2.2 Analysis by Treatment
8 Schizophrenia Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Schizophrenia Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Schizophrenia Market Segmentation (2017-2032) - 8 Major Markets
11.1 Schizophrenia Market (2017-2032) by Type
11.1.1 Market Overview
11.1.2 Paranoid Schizophrenia
11.1.3 Hebephrenic Schizophrenia
11.1.4 Catatonic Schizophrenia
11.1.5 Undifferentiated Schizophrenia
11.2 Schizophrenia Market (2017-2032) by Treatment
11.2.1 Market Overview
11.2.2 Second Generation Antipsychotics
11.2.2.1 Invega (Paliperidone)
11.2.2.2 Zyprexa (Olanzapine)
11.2.2.3 Geodon (Ziprasidone)
11.2.2.4 Seoquel(Quetiapine)
11.2.2.5 Latuda (Lurasidone)
11.2.2.6 Saphris (Asenapine)
11.2.2.7 Vraylar (Cariprazine)
11.2.2.8 Risperdal (Risperidone)
11.2.3 Third Generation Antipsychotics
11.2.3.1 Abilify (Aripiprazole)
11.3 Schizophrenia Market (2017-2032) by Route of Administration
11.3.1 Oral
11.3.2 Injectable
11.3.3 Spinal Tap
11.3.4 Muscle Biopsy
11.3.5 Others
11.4 Schizophrenia Market (2017-2032) by End User
11.4.1 Market Overview
11.4.2 Hospitals & Clinics
11.4.3 Cancer Research Centers
11.4.4 Others
11.5 Schizophrenia Market (2017-2032) by Distribution Channel
11.5.1 Market Overview
11.5.2 Hospital Pharmacy
11.5.3 Retail Pharmacy
11.5.4 Online Pharmacy
11.5.5 Others
11.6 Schizophrenia Market (2017-2032) by Region
11.6.1 Market Overview
11.6.2 United States
11.6.3 EU-4 and the United Kingdom
11.6.3.1 Germany
11.6.3.2 France
11.6.3.3 Italy
11.6.3.4 Spain
11.6.3.5 United Kingdom
11.6.4 Japan
11.6.5 India
12 United States Schizophrenia Market (2017-2032)
12.1 United States Schizophrenia Market Historical Value (2017-2023)
12.2 United States Schizophrenia Market Forecast Value (2024-2032)
12.3 United States Schizophrenia Market (2017-2032) by Type
12.3.1 Market Overview
12.3.2 Paranoid Schizophrenia
12.3.3 Hebephrenic Schizophrenia
12.3.4 Catatonic Schizophrenia
12.3.5 Undifferentiated Schizophrenia
12.4 United States Schizophrenia Market (2017-2032) by Route of Administration
12.4.1 Market Overview
12.4.2 Oral
12.4.3 Injectable
12.4.4 Spinal Tap
12.4.5 Muscle Biopsy
12.4.6 Others
13 EU-4 and United Kingdom Schizophrenia Market (2017-2032)
13.1 EU-4 and United Kingdom Schizophrenia Market Historical Value (2017-2023)
13.2 EU-4 and United Kingdom Schizophrenia Market Forecast Value (2024-2032)
13.3 EU-4 and United Kingdom Schizophrenia Market Overview
13.4 EU-4 and United Kingdom Schizophrenia Market (2017-2032) by Type
13.4.1 Market Overview
13.4.2 Paranoid Schizophrenia
13.4.3 Hebephrenic Schizophrenia
13.4.4 Catatonic Schizophrenia
13.4.5 Undifferentiated Schizophrenia
13.5 EU-4 and United Kingdom Schizophrenia Market (2017-2032) by Route of Administration
13.5.1 Market Overview
13.5.2 Oral
13.5.3 Injectable
13.5.4 Spinal Tap
13.5.5 Muscle Biopsy
13.5.6 Others
14 Japan Schizophrenia Market
14.1 Japan Schizophrenia Market Historical Value (2017-2023)
14.2 Japan Schizophrenia Market Forecast Value (2024-2032)
14.3 Japan Schizophrenia Market (2017-2032) by Type
14.3.1 Market Overview
14.3.2 Paranoid Schizophrenia
14.3.3 Hebephrenic Schizophrenia
14.3.4 Catatonic Schizophrenia
14.3.5 Undifferentiated Schizophrenia
14.4 Japan Schizophrenia Market (2017-2032) by Route of Administration
14.4.1 Market Overview
14.4.2 Oral
14.4.3 Injectable
14.4.4 Spinal Tap
14.4.5 Muscle Biopsy
14.4.6 Others
15 India Schizophrenia Market
15.1 India Schizophrenia Market (2017-2032) Historical Value (2017-2023)
15.2 India Schizophrenia Market (2017-2032) Forecast Value (2024-2032)
15.3 India Schizophrenia Market (2017-2032) by Type
15.3.1 Market Overview
15.3.2 Paranoid Schizophrenia
15.3.3 Hebephrenic Schizophrenia
15.3.4 Catatonic Schizophrenia
15.3.5 Undifferentiated Schizophrenia
15.4 India Schizophrenia Market (2017-2032) by Route of Administration
15.4.1 Market Overview
15.4.2 Oral
15.4.3 Injectable
15.4.4 Spinal Tap
15.4.5 Muscle Biopsy
15.4.6 Others
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 Japan PMDA
16.1.4 Others
17 Patent Analysis
17.1 Analysis by Type of Patent
17.2 Analysis by Publication Year
17.3 Analysis by Issuing Authority
17.4 Analysis by Patent Age
17.5 Analysis by CPC Analysis
17.6 Analysis by Patent Valuation
17.7 Analysis by Key Players
18 Grants Analysis
18.1 Analysis by Year
18.2 Analysis by Amount Awarded
18.3 Analysis by Issuing Authority
18.4 Analysis by Grant Application
18.5 Analysis by Funding Institute
18.6 Analysis by NIH Departments
18.7 Analysis by Recipient Organization
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Funding and Investment Analysis
20.1 Analysis by Funding Instances
20.2 Analysis by Type of Funding
20.3 Analysis by Funding Amount
20.4 Analysis by Leading Players
20.5 Analysis by Leading Investors
20.6 Analysis by Geography
21 Partnership and Collaborations Analysis
21.1 Analysis by Partnership Instances
21.2 Analysis by Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Supplier Landscape
22.1 Johnson & Johnson
22.1.1 Financial Analysis
22.1.2 Product Portfolio
22.1.3 Demographic Reach and Achievements
22.1.4 Mergers and Acquisitions
22.1.5 Certifications
22.2 Bristol Myers Squibb
22.2.1 Financial Analysis
22.2.2 Product Portfolio
22.2.3 Demographic Reach and Achievements
22.2.4 Mergers and Acquisitions
22.2.5 Certifications
22.3 AstraZeneca
22.3.1 Financial Analysis
22.3.2 Product Portfolio
22.3.3 Demographic Reach and Achievements
22.3.4 Mergers and Acquisitions
22.3.5 Certifications
22.4 Eli Lilly And Company
22.4.1 Financial Analysis
22.4.2 Product Portfolio
22.4.3 Demographic Reach and Achievements
22.4.4 Mergers and Acquisitions
22.4.5 Certifications
22.5 Sumitomo Dainippon Pharma
22.5.1 Financial Analysis
22.5.2 Product Portfolio
22.5.3 Demographic Reach and Achievements
22.5.4 Mergers and Acquisitions
22.5.5 Certifications
22.6 Pfizer Inc.
22.6.1 Financial Analysis
22.6.2 Product Portfolio
22.6.3 Demographic Reach and Achievements
22.6.4 Mergers and Acquisitions
22.6.5 Certifications
22.7 Vanda Pharmaceuticals
22.7.1 Financial Analysis
22.7.2 Product Portfolio
22.7.3 Demographic Reach and Achievements
22.7.4 Mergers and Acquisitions
22.7.5 Certifications
22.8 Allergan
22.8.1 Financial Analysis
22.8.2 Product Portfolio
22.8.3 Demographic Reach and Achievements
22.8.4 Mergers and Acquisitions
22.8.5 Certifications
22.9 H. Lundbeck A/S
22.9.1 Financial Analysis
22.9.2 Product Portfolio
22.9.3 Demographic Reach and Achievements
22.9.4 Mergers and Acquisitions
22.9.5 Certifications
22.10 Alkermes plc
22.10.1 Financial Analysis
22.10.2 Product Portfolio
22.10.3 Demographic Reach and Achievements
22.10.4 Mergers and Acquisitions
22.10.5 Certifications
22.11 AbbVie Inc.
22.11.1 Financial Analysis
22.11.2 Product Portfolio
22.11.3 Demographic Reach and Achievements
22.11.4 Mergers and Acquisitions
22.11.5 Certifications
22.12 Acadia Pharmaceuticals
22.12.1 Financial Analysis
22.12.2 Product Portfolio
22.12.3 Demographic Reach and Achievements
22.12.4 Mergers and Acquisitions
22.12.5 Certifications
List not exhaustive
23 Schizophrenia Treatment Drugs - Distribution Model (Additional Insight)
23.1 Overview
23.2 Potential Distributors
23.3 Key Parameters for Distribution Partner Assessment
24 Key Opinion Leaders (KOL) Insights (Additional Insight)
25 Company Competitiveness Analysis (Additional Insight)
25.1 Very Small Companies
25.2 Small Companies
25.3 Mid-Sized Companies
25.4 Large Companies
25.5 Very Large Companies
26 Payment Methods (Additional Insight)
26.1 Government Funded
26.2 Private Insurance
26.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The research team strives to make this section as comprehensive as possible.

Companies Mentioned

  • Johnson & Johnson
  • Bristol Myers Squibb
  • AstraZeneca
  • Eli Lilly And Company
  • Sumitomo
  • Dainippon Pharma
  • Pfizer Inc.
  • Vanda Pharmaceuticals
  • Allergan H. Lundbeck A/S
  • Alkermes plc
  • AbbVie Inc.
  • Acadia Pharmaceuticals

Methodology

Loading
LOADING...